Vistin Pharma ASA
Vistin Pharma ASA, through its subsidiary, Vistin Pharma AS, engages in the production and sale of active pharmaceutical ingredients (APIs) worldwide. It offers metformin HCl APIs and direct compressive granulates for the pharmaceutical industry. The company was founded in 1969 and is based in Oslo, Norway.
Market Cap & Net Worth: Vistin Pharma ASA (VISTN)
Vistin Pharma ASA (OL:VISTN) has a market capitalization of $85.62 Million (Nkr975.58 Million) as of March 18, 2026. Listed on the OL stock exchange, this Norway-based company holds position #22239 globally and #113 in its home market, demonstrating a 4.76% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vistin Pharma ASA's stock price Nkr22.00 by its total outstanding shares 44344592 (44.34 Million).
Vistin Pharma ASA Market Cap History: 2015 to 2026
Vistin Pharma ASA's market capitalization history from 2015 to 2026. Data shows growth from $63.18 Million to $85.62 Million (4.97% CAGR).
Vistin Pharma ASA Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vistin Pharma ASA's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.21x
Vistin Pharma ASA's market cap is 0.21 times its annual revenue
1.02x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
1.47x
Vistin Pharma ASA's market cap is 1.47 times its annual earnings
10.35x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $72.93 Million | $170.51 Million | $12.92 Million | 0.43x | 5.65x |
| 2017 | $41.11 Million | $176.69 Million | $70.40 Million | 0.23x | 0.58x |
| 2018 | $24.30 Million | $198.99 Million | -$73.63 Million | 0.12x | N/A |
| 2019 | $33.87 Million | $227.19 Million | $66.20 Million | 0.15x | 0.51x |
| 2020 | $61.69 Million | $253.16 Million | -$96.95 Million | 0.24x | N/A |
| 2021 | $70.01 Million | $278.62 Million | $24.95 Million | 0.25x | 2.81x |
| 2022 | $57.07 Million | $287.68 Million | -$4.72 Million | 0.20x | N/A |
| 2023 | $84.17 Million | $435.39 Million | $45.60 Million | 0.19x | 1.85x |
| 2024 | $92.24 Million | $429.09 Million | $62.75 Million | 0.21x | 1.47x |
Competitor Companies of VISTN by Market Capitalization
Companies near Vistin Pharma ASA in the global market cap rankings as of March 18, 2026.
Key companies related to Vistin Pharma ASA by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Vistin Pharma ASA Historical Marketcap From 2015 to 2026
Between 2015 and today, Vistin Pharma ASA's market cap moved from $63.18 Million to $ 85.62 Million, with a yearly change of 4.97%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Nkr85.62 Million | +5.77% |
| 2025 | Nkr80.95 Million | -12.24% |
| 2024 | Nkr92.24 Million | +9.59% |
| 2023 | Nkr84.17 Million | +47.47% |
| 2022 | Nkr57.07 Million | -18.47% |
| 2021 | Nkr70.01 Million | +13.48% |
| 2020 | Nkr61.69 Million | +82.13% |
| 2019 | Nkr33.87 Million | +39.41% |
| 2018 | Nkr24.30 Million | -40.91% |
| 2017 | Nkr41.11 Million | -43.63% |
| 2016 | Nkr72.93 Million | +15.43% |
| 2015 | Nkr63.18 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Vistin Pharma ASA was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $85.62 Million USD |
| MoneyControl | $85.62 Million USD |
| MarketWatch | $85.62 Million USD |
| marketcap.company | $85.62 Million USD |
| Reuters | $85.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.